Trifluoroacetic acid pentafluorophenyl ester

We are Trifluoroacetic acid pentafluorophenyl ester CAS:14533-84-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Trifluoroacetic acid pentafluorophenyl ester
CAS.NO:14533-84-7
Synonyms:Perfluorophenyl 2,2,2-trifluoroacetate;Pentafluorphenyl trifluoracetate;(2,3,4,5,6-pentafluorophenyl) 2,2,2-trifluoroacetate;
Molecular Formula:C8F8O2
Molecular Weight:280.07200
 
Physical and Chemical Properties:
Density:1.63;
Melting point:2oC;
Boiling point:122-123oC;
Flash point:126oC;
Index of Refraction:1.368;
 
HS Code: 2915900090
UN No.: UN3272
Hazard class: 3 categories 
Packing level: Class III
 
Specification:
Appearance:Colorless transparent liquid
Purity(GC):≥98.0%

Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As a condensation reagent


Trifluoroacetic acid pentafluorophenyl ester


Related News: Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.1416134-48-9 Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.sodio, 4-cloro-1-hidroxibutano-1-sulfonato CAS:54322-20-2 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.53596-82-0 Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”

Related Products
Product Name
1-β-D-Arabinofuranosyluracil View Details
2-METHOXYETHYLAMINE View Details
(R)-2,3-Dihydro-1H-Inden-1-Amine Hydrochloride View Details
cue-lure Cas:3572-06-3 manufacturer 2,6-Dichlorobenzaldehyde manufacturer 1-Chloro-3,5-di(4-chlorbenzoyl)-2-deoxy-D-ribose manufacturer 1-(bromomethyl)-2-(trifluoromethoxy)benzene manufacturer Dimethylcarbamoyl chloride manufacturer